Viatris (NASDAQ: VTRS) — Perfil da empresa, notícias e dados financeiros
Viatris is a global healthcare company producing primary care medicines, focusing on accessibility and affordability in healthcare.
Viatris
Viatris is a global healthcare company engaged in the development, manufacturing, and commercialization of prescription and over-the-counter pharmaceuticals. The company operates across four main business segments: Developed Markets, Greater China, JANZ (Japan, Australia, and New Zealand), and Emerging Markets. Its commercial portfolio comprises established iconic brands, generic medicines including complex generics and biosimilars, and innovative novel therapies. Viatris covers diverse therapeutic areas such as cardiovascular health, central nervous system disorders, oncology, immunology, infectious diseases, and gastroenterology. The organization distributes medications globally across more than 165 countries and territories through its integrated manufacturing, packaging, regulatory, and distribution network.
Resumo
Operações
Produtos e/ou serviços de Viatris
- Developed Markets Operations: Commercialization of off-patent branded medicines, generic drugs, complex generics, and biosimilars across North America and Europe, supplying healthcare systems, retail pharmacy chains, wholesalers, and hospital networks through established distribution channels.
- Emerging Markets Operations: Marketing and distribution of essential prescription pharmaceuticals, branded generics, and over-the-counter health products across Latin America, Southeast Asia, South Asia, the Middle East, and Africa to broaden patient access.
- Greater China Operations: Commercial distribution of prescription pharmaceuticals, legacy brand therapies, and specialized localized formulations to medical centers, public hospitals, retail pharmacies, and healthcare institutions across mainland China, Hong Kong, and Taiwan.
- JANZ Regional Operations: Sales and commercial distribution of established original brand formulations, generic prescription medicines, and specialty healthcare treatments across Japan, Australia, and New Zealand, supported by localized regulatory and commercial operations.
- Established Brands and Generics: Global manufacturing and marketing of off-patent original branded medicines and complex generic pharmaceuticals across core therapeutic areas, including cardiovascular health, central nervous system disorders, gastroenterology, and infectious disease management.
- Innovative Novel Therapies: Clinical development, regulatory advancement, and worldwide commercial launch of proprietary pharmaceutical therapies, specialized formulations, and first-in-class prescription treatments designed to address targeted therapeutic areas and significant unmet medical needs.
equipe executiva do Viatris
- Scott Andrew SmithCEO & Director
- Andrew EnriettiChief Administrative & Transformation Officer
- Corinne M. Le GoffChief Commercial Officer
- Paul B. CampbellInterim CFO, Chief Accounting Officer & Corporate Controller
- Ramkumar V. RayapureddyChief Information Officer
- William SzablewskiHead of Investor Relations & Capital Markets
- Matthew Joseph MalettaChief Legal Officer
- Lara RamsburgChief People & Corporate Affairs Officer
- Philippe MartinChief R&D Officer
- Peter McCormickChief Supply Officer
Últimas notícias sobre a Viatris
Histórico de dividendos
Dividendos por ação pagos pela Viatris, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2026(até o momento) | — | — | — | $0.3600 |
| FY2025 | — | — | — | $0.4800 |
| FY2024 | — | — | — | $0.4800 |
| FY2023 | — | — | — | $0.4800 |
| FY2022 | — | — | — | $0.4800 |
Principais indicadores financeiros
Resultados divulgados pela Viatris, em USD.
- Cap. de mercado
- 21,5 bi
- Receita (TTM)
- 14,7 bi
- P/L
- —
- LPA (diluído, TTM)
- -0.4
- Dividend yield
- 2.6%
- Margem de lucro
- -2.8%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 14,3 bi | -2,7 bi | -3,5 bi | |
| 14,7 bi | 10,1 mi | -634,2 mi | |
| 15,4 bi | 766,2 mi | 54,7 mi | |
| 16,3 bi | 1,6 bi | 2,1 bi |